High-dose treatment of refractory arrhythmias propafenone Experience.docVIP

 PAGE \* MERGEFORMAT 5 High-dose treatment of refractory arrhythmias propafenone Experience [Keywords:] Propafenone, treatment, refractory arrhythmia Propafenone as a new class Ic antiarrhythmic drugs, with a wide range of anti-arrhythmic effect. The author of the 10 cases of patients with refractory arrhythmia heart rate level after the higher dose achieved satisfactory results, is a brief report and analysis as follows. 1 Clinical data 1.1 General information on 10 cases of arrhythmia patients, 7 males and 3 females, aged 18 to 63 years, mean 52 years. 5 patients with paroxysmal atrial fibrillation, paroxysmal supraventricular tachycardia in 2 cases, ventricular heart tachycardia in 3 patients. the primary disease in 5 cases of coronary heart disease (myocardial infarction within 1 case, 1 case of old myocardial infarction, pre-excitation syndrome in 1 case, 1 case of hypertrophic cardiomyopathy, viral myocarditis and 1 case of idiopathic 2 cases of atrial fibrillation. heart function 8 cases of grade , grade 2 cases. 1.2 Methods drug dosage in this group from 600mg / d orally 3 times starting with 3 to 5 days, such as invalid, every 3 days increased 150 ~ 200mg / d, until transferred to sinus rhythm. This group when cardioversion dose of 800 ~ 1000mg / d, 7 cases of 1000mg, 3 cases of 800mg, maintenance dose is 300 ~ 600mg / d, maintenance treatment time of a minimum of 3 months and a maximum 3-year average of 1 year. 1.3 The effect of 10 cases of refractory supraventricular tachycardia has anti-arrhythmic drugs or through other conventional volume Propafenone treatment efficacy are not satisfied, increase the doses were converted to sinus rhythm. Which 1 patients with persistent ventricular tachycardia 20 days, multi-drug treatment fails, switch to propafenone from 600mg / d to 1000mg / d, qd for 3 days, the ventricular tachycardia disappeared, and 600mg / d adhere to 3 months, 1 week because of their own withdrawal The VT recurrence, onc